The DOI matches its Crossref record; 87 of the 87 references it cites were found in a registry or an index.
Triple-negative breast cancer: is there a treatment on the horizon?
Open accessAbstract
// Hui Yao 1 , Guangchun He 1 , Shichao Yan 1 , Chao Chen 1 , Liujiang Song 2 , Thomas J. Rosol 3 and Xiyun Deng 1 1 Department of Pathology, Hunan Normal University Medical College, Changsha, Hunan, China 2 Department of Pediatrics, Hunan Normal University Medical College, Changsha, Hunan, China 3 Department of Veterinary Biosciences, The Ohio State University, Columbus, Ohio, USA Correspondence to: Xiyun Deng, email: // Keywords : breast cancer, triple-negative, therapeutics Received : May 12, 2016 Accepted : September 17, 2016 Published : September 27, 2016 Abstract Triple-negative breast cancer (TNBC), which accounts for 15–20% of all breast cancers, does not express estrogen receptor (ER) or progesterone receptor (PR) and lacks human epidermal growth factor receptor 2 (HER2) overexpression or amplification. These tumors have a more aggressive phenotype and a poorer prognosis due to the high propensity for metastatic progression and absence of specific targeted treatments. Patients with TNBC do not benefit from hormonal or trastuzumab-based targeted therapies because of the loss of target receptors. Although these patients respond to chemotherapeutic agents such as taxanes and anthracyclines better than other subtypes of breast cancer, prognosis remains poor. A group of targeted therapies under investigation showed favorable results in TNBC, especially in cancers with BRCA mutation. The lipid-lowering statins (3-hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors), including lovastatin and simvastatin, have been shown to preferentially target TNBC compared with non-TNBC. These statins hold great promise for the management of TNBC. Only with the understanding of the molecular basis for the preference of statins for TNBC and more investigations in clinical trials can they be reformulated into a clinically approved drug against TNBC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
METABRIC Group, Curtis, C., Shah, S. P., Chin, S.-F., Turashvili, G., Rueda, O. M., Dunning, M. J., Speed, D., Lynch, A. G., Samarajiwa, S., et al. (2012) · Nature · doi:10.1038/nature10983 · Cited by 6,097
Lehmann, B. D., Bauer, J. A., Chen, X., Sanders, M. E., Chakravarthy, A. B., Shyr, Y., & Pietenpol, J. A. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45014 · Cited by 5,592
Repeated observation of breast tumor subtypes in independent gene expression data sets
Sørlie, T., Tibshirani, R., Parker, J., Hastie, T., Marron, J. S., Nobel, A., Deng, S., Johnsen, H., Pesich, R., Geisler, S., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0932692100 · Cited by 5,429
Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer Study
Carey, L. A., Perou, C. M., Livasy, C. A., Dressler, L. G., Cowan, D., Conway, K., Karaca, G., Troester, M. A., Tse, C. K., Edmiston, S., et al. (2006) · JAMA · doi:10.1001/jama.295.21.2492 · Cited by 3,819
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
Liedtke, C., Mazouni, C., Hess, K. R., André, F., Tordai, A., Mejia, J. A., Symmans, W. F., Gonzalez-Angulo, A. M., Hennessy, B., Green, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.4147 · Cited by 2,892
Nielsen, T. O., Hsu, F. D., Jensen, K., Cheang, M., Karaca, G., Hu, Z., Hernandez-Boussard, T., Livasy, C., Cowan, D., Dressler, L., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0220 · Cited by 2,663
Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60893-8 · Cited by 2,279
The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes
Carey, L. A., Dees, E. C., Sawyer, L., Gatti, L., Moore, D. T., Collichio, F., Ollila, D. W., Sartor, C. I., Graham, M. L., & Perou, C. M. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1109 · Cited by 2,087
Tutt, A., Robson, M., Garber, J. E., Domchek, S. M., Audeh, M. W., Weitzel, J. N., Friedlander, M., Arun, B., Loman, N., Schmutzler, R. K., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60892-6 · Cited by 1,655
Deconstructing the molecular portraits of breast cancer
Prat, A., & Perou, C. M. (2011) · Molecular Oncology · doi:10.1016/j.molonc.2010.11.003 · Cited by 1,343
Herschkowitz, J. I., Simin, K., Weigman, V. J., Mikaelian, I., Usary, J., Hu, Z., Rasmussen, K. E., Jones, L. P., Assefnia, S., Chandrasekharan, S., et al. (2007) · Genome Biology · doi:10.1186/gb-2007-8-5-r76 · Cited by 1,285
Cheang, M. C. U., Voduc, D., Bajdik, C., Leung, S., McKinney, S., Chia, S. K., Perou, C. M., & Nielsen, T. O. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1658 · Cited by 1,195
Basal-Like Breast Cancer: A Critical Review
Rakha, E. A., Reis-Filho, J. S., & Ellis, I. O. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.1748 · Cited by 1,164
Gelmon, K. A., Tischkowitz, M., Mackay, H., Swenerton, K., Robidoux, A., Tonkin, K., Hirte, H., Huntsman, D., Clemons, M., Gilks, B., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70214-5 · Cited by 1,117
Weekly Paclitaxel in the Adjuvant Treatment of Breast Cancer
Sparano, J. A., Wang, M., Martino, S., Jones, V., Perez, E. A., Saphner, T., Wolff, A. C., Sledge, G. W., Wood, W. C., & Davidson, N. E. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707056 · Cited by 997
Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway
Freed-Pastor, W. A., Mizuno, H., Zhao, X., Langerød, A., Moon, S.-H., Rodriguez-Barrueco, R., Barsotti, A., Chicas, A., Li, W., Polotskaia, A., et al. (2012) · Cell · doi:10.1016/j.cell.2011.12.017 · Cited by 865
Lin, N. U., Claus, E., Sohl, J., Razzak, A. R., Arnaout, A., & Winer, E. P. (2008) · Cancer · doi:10.1002/cncr.23930 · Cited by 727
Biology, Metastatic Patterns, and Treatment of Patients with Triple-Negative Breast Cancer
Anders, C. K., & Carey, L. A. (2009) · Clinical Breast Cancer · doi:10.3816/cbc.2009.s.008 · Cited by 625
Morris, G. J., Naidu, S., Topham, A. K., Guiles, F., Xu, Y., McCue, P., Schwartz, G. F., Park, P. K., Rosenberg, A. L., Brill, K., et al. (2007) · Cancer · doi:10.1002/cncr.22836 · Cited by 602
Molecular Stratification of Triple-Negative Breast Cancers
Perou, C. M. (2011) · The Oncologist · doi:10.1634/theoncologist.2011-s1-61 · Cited by 582
Molecular Characterization of Basal-Like and Non-Basal-Like Triple-Negative Breast Cancer
Prat, A., Adamo, B., Cheang, M. C. U., Anders, C. K., Carey, L. A., & Perou, C. M. (2013) · The Oncologist · doi:10.1634/theoncologist.2012-0397 · Cited by 568
Weigelt, B., Horlings, H., Kreike, B., Hayes, M., Hauptmann, M., Wessels, L., de Jong, D., Van de Vijver, M., Veer, L. V., & Peterse, J. (2008) · The Journal of Pathology · doi:10.1002/path.2407 · Cited by 562
Current approaches in treatment of triple-negative breast cancer.
Wahba, H. A., & El-Hadaad, H. A. (2015) · PubMed · doi:10.7497/j.issn.2095-3941.2015.0030 · Cited by 538
Base Excision Repair Is Impaired in Mammalian Cells Lacking Poly(ADP-ribose) Polymerase-1
Dantzer, F., de la Rubia, G., Ménissier-de Murcia, J., Hostomsky, Z., de Murcia, G., & Schreiber, V. (2000) · Biochemistry · doi:10.1021/bi0003442 · Cited by 505
Carey, L. A., Rugo, H. S., Marcom, P. K., Mayer, E. L., Esteva, F. J., Ma, C. X., Liu, M. C., Storniolo, A. M., Rimawi, M. F., Forero-Torres, A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.5579 · Cited by 499
Triple-Negative Breast Cancer: Distinguishing between Basal and Nonbasal Subtypes
Rakha, E. A., Elsheikh, S. E., Aleskandarany, M. A., Habashi, H. O., Green, A. R., Powe, D. G., El-Sayed, M. E., Benhasouna, A., Brunet, J.-S., Akslen, L. A., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2132 · Cited by 489
Pharmacological Actions of Statins: A Critical Appraisal in the Management of Cancer
Gazzerro, P., Proto, M. C., Gangemi, G., Malfitano, A. M., Ciaglia, E., Pisanti, S., Santoro, A., Laezza, C., & Bifulco, M. (2012) · Pharmacological Reviews · doi:10.1124/pr.111.004994 · Cited by 457
Herbst, R. S., & Shin, D. M. (2002) · Cancer · doi:10.1002/cncr.10372 · Cited by 446
How basal are triple‐negative breast cancers?
Bertucci, F., Finetti, P., Cervera, N., Esterni, B., Hermitte, F., Viens, P., & Birnbaum, D. (2008) · International Journal of Cancer · doi:10.1002/ijc.23518 · Cited by 443
Koeneman, K. S., Yeung, F., & Chung, L. W. K. (1999) · The Prostate · doi:10.1002/(sici)1097-0045(19990601)39:4<246::aid-pros5>3.0.co;2-u · Cited by 440
Esserman, L. J., Berry, D. A., DeMichele, A., Carey, L., Davis, S. E., Buxton, M., Hudis, C., Gray, J. W., Perou, C., Yau, C., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.2779 · Cited by 438
Finn, R. S., Dering, J., Ginther, C., Wilson, C. A., Glaspy, P., Tchekmedyian, N., & Slamon, D. J. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9463-x · Cited by 409
Statin Prescriptions and Breast Cancer Recurrence Risk: A Danish Nationwide Prospective Cohort Study
Ahern, T. P., Pedersen, L., Tarp, M., Cronin-Fenton, D. P., Garne, J. P., Silliman, R. A., Sorensen, H. T., & Lash, T. L. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr291 · Cited by 387
Gennari, A., Sormani, M. P., Pronzato, P., Puntoni, M., Colozza, M., Pfeffer, U., & Bruzzi, P. (2008) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djm252 · Cited by 371
Adjuvant Dose-Dense Chemotherapy in Breast Cancer: Standard of Care in High-Risk Patients
Möbus, V. (2016) · Breast Care · doi:10.1159/000444004 · Cited by 354
Understanding and treating triple-negative breast cancer
Carey, L., & Anders, C. (2021) · PubMed · doi:10.17615/85ph-f542 · Cited by 351
Breast Cancer Growth Prevention by Statins
Campbell, M. J., Esserman, L. J., Zhou, Y., Shoemaker, M., Lobo, M., Borman, E., Baehner, F., Kumar, A. S., Adduci, K., Marx, C., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4061 · Cited by 348
Linderholm, B. K., Hellborg, H., Johansson, U., Elmberger, G., Skoog, L., Lehtiö, J., & Lewensohn, R. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp062 · Cited by 347
Characteristics of triple-negative breast cancer
de Ruijter, T. C., Veeck, J., de Hoon, J. P. J., van Engeland, M., & Tjan-Heijnen, V. C. (2011) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-010-0957-x · Cited by 317
Basal-like breast carcinomas: clinical outcome and response to chemotherapy
Banerjee, S., Reis-Filho, J. S., Ashley, S., Steele, D., Ashworth, A., Lakhani, S. R., & Smith, I. E. (2006) · Journal of Clinical Pathology · doi:10.1136/jcp.2005.033043 · Cited by 290
Cancer risk among statin users: A population‐based cohort study
Friis, S., Poulsen, A. H., Johnsen, S. P., McLaughlin, J. K., Fryzek, J. P., Dalton, S. O., Sørensen, H. T., & Olsen, J. H. (2005) · International Journal of Cancer · doi:10.1002/ijc.20758 · Cited by 275
A Review of Triple-Negative Breast Cancer
Ismail-Khan, R., & Bui, M. M. (2010) · Cancer Control · doi:10.1177/107327481001700305 · Cited by 254
Triple-Negative Breast Cancer: Epidemiology and Management Options
Dawood, S. (2010) · Drugs · doi:10.2165/11538150-000000000-00000 · Cited by 253
Chacón, R. D., & Costanzo, M. V. (2010) · Breast Cancer Research · doi:10.1186/bcr2574 · Cited by 239
Bonovas, S., Filioussi, K., Tsavaris, N., & Sitaras, N. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.7045 · Cited by 233
Sihto, H., Lundin, J., Lundin, M., Lehtimäki, T., Ristimäki, A., Holli, K., Sailas, L., Kataja, V., Turpeenniemi-Hujanen, T., Isola, J., et al. (2011) · Breast Cancer Research · doi:10.1186/bcr2944 · Cited by 229
Miles, D. W., Diéras, V., Cortés, J., Duenne, A.-A., Yi, J., & O'Shaughnessy, J. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt276 · Cited by 228
Long-term Use of Cholesterol-Lowering Drugs and Cancer Incidence in a Large United States Cohort
Jacobs, E. J., Newton, C. C., Thun, M. J., & Gapstur, S. M. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2953 · Cited by 222
Platinum-based chemotherapy in triple-negative breast cancer
Sirohi, B., Arnedos, M., Popat, S., Ashley, S., Nerurkar, A., Walsh, G., Johnston, S., & Smith, I. E. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn395 · Cited by 220
Genetic Alterations and Oncogenic Pathways Associated with Breast Cancer Subtypes
Hu, X., Stern, H. M., Ge, L., O'Brien, C., Haydu, L., Honchell, C. D., Haverty, P. M., Peters, B. A., Wu, T. D., Amler, L. C., et al. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0107 · Cited by 217
Molecular Stratification of Triple-Negative Breast Cancers
Perou, C. M. (2010) · The Oncologist · doi:10.1634/theoncologist.2010-s5-39 · Cited by 203
Viale, G., Rotmensz, N., Maisonneuve, P., Bottiglieri, L., Montagna, E., Luini, A., Veronesi, P., Intra, M., Torrisi, R., Cardillo, A., et al. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0206-z · Cited by 190
Statin Use and Breast Cancer: Prospective Results From the Women's Health Initiative
Cauley, J. A., McTiernan, A., Rodabough, R. J., LaCroix, A., Bauer, D. C., Margolis, K. L., Paskett, E. D., Vitolins, M. Z., Furberg, C. D., & Chlebowski, R. T. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj188 · Cited by 179
Hastak, K., Alli, E., & Ford, J. M. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4521 · Cited by 176
Triple-Negative Breast Cancer and the Need for New Therapeutic Targets
Engebraaten, O., Vollan, H. K. M., & Børresen-Dale, A.-L. (2013) · The American Journal of Pathology · doi:10.1016/j.ajpath.2013.05.033 · Cited by 175
Molecular Pathways: How Can BRCA-Mutated Tumors Become Resistant to PARP Inhibitors?
Bouwman, P., & Jonkers, J. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0225 · Cited by 158
Statin use and risk of breast cancer: a meta-analysis of observational studies
Undela, K., Srikanth, V., & Bansal, D. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2154-x · Cited by 155
Mueck, A. O., Seeger, H., & Wallwiener, D. R. (2003) · Menopause The Journal of The North American Menopause Society · doi:10.1097/01.gme.0000055485.06076.00 · Cited by 151
Statin Use and the Risk of Breast and Prostate Cancer
Coogan, P. F., Rosenberg, L. A., Palmer, J. R., Strom, B. L., Zauber, A. G., & Shapiro, S. (2002) · Epidemiology · doi:10.1097/00001648-200205000-00005 · Cited by 137
Diaz, L. K., Cryns, V. L., Symmans, W. F., & Sneige, N. (2007) · Advances in Anatomic Pathology · doi:10.1097/pap.0b013e3181594733 · Cited by 132
Patterns of recurrence in the basal and non-basal subtypes of triple-negative breast cancers
Nofech‐Mozes, S., Trudeau, M., Kahn, H. K., Dent, R. A., Rawlinson, E., Sun, P., Narod, S. A., & Hanna, W. M. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0295-8 · Cited by 116
Phase II Genomics Study of Ixabepilone as Neoadjuvant Treatment for Breast Cancer
Baselga, J. M., Zambetti, M., Llombart‐Cussac, A., Manikhas, G., Kubista, E., Steger, G. G., Makhson, A. N., Tjulandin, S., Ludwig, H., Verrill, M. W., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.2646 · Cited by 113
Maloberti, P. M., Duarte, A., Orlando, U. D., Pasqualini, M. E., Solano, A. R., López-Otı́n, C., & Podesta, E. J. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015540 · Cited by 109
Staudacher, L., Cottu, P. H., Dieras, V. C., Vincent‐Salomon, A., Guilhaume, M. N., Escalup, L., Dorval, T., Beuzeboc, P., Mignot, L., & Pierga, J. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq461 · Cited by 87
Monaco, M. E., Creighton, C. J., Lee, P., Zou, X., Topham, M. K., & Stafforini, D. M. (2010) · Translational Oncology · doi:10.1593/tlo.09202 · Cited by 86
Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer
Martín, M., Rodríguez-Lescure, Á., Ruı́z, A., Alba, E., Calvo, L., Ruíz‐Borrego, M., Santaballa, A., Rodriguez, C. A., Crespo, C., Abad, M., et al. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0663-z · Cited by 81
EGFR as paradoxical predictor of chemosensitivity and outcome among triple-negative breast cancer
Nogi (1994) · Oncology Reports · doi:10.3892/or_00000238 · Cited by 78
Statin use and breast cancer survival and risk: a systematic review and meta-analysis
Wu, Q., Tu, C., Li, Y., Zhu, J., Qian, K., Li, W., & Wu, L. (2015) · Oncotarget · doi:10.18632/oncotarget.5557 · Cited by 68
Gene expression profiling in breast cancer
Morris, S. R., & Carey, L. (2007) · Current Opinion in Oncology · doi:10.1097/cco.0b013e3282f0ada3 · Cited by 67
Villanueva, C., Awada, A. H., Campone, M., et al. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.01.001 · Cited by 65
Desidero, T. D., Xu, P., Man, S., Bocci, G., & Kerbel, R. S. (2015) · Oncotarget · doi:10.18632/oncotarget.6377 · Cited by 65
Nickels, S., Vrieling, A., Seibold, P., Heinz, J., Obi, N., Flesch‐Janys, D., & Chang-Claude, J. C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0075088 · Cited by 64
Biology, Metastatic Patterns, and Treatment of Patients With Triple-Negative Breast Cancer
Anders, C. K., & Carey, L. (2009) · Clinical Cancer Reviews · doi:10.3816/ccr.2009.n.005 · Cited by 64
Identifying molecular features that distinguish fluvastatin-sensitive breast tumor cells
Goard, C. A., Chan‐Seng‐Yue, M., Mullen, P., Quiroga, A. D., Wasylishen, A. R., Clendening, J. W., Sendorek, D. H. S., Haider, S. A., Lehner, R. S., Boutros, P. C., et al. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2800-y · Cited by 62
Statin induces inhibition of triple negative breast cancer (TNBC) cells via PI3K pathway
Park, Y. H., Jung, H. H., Ahn, J. S., & Im, Y. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.08.043 · Cited by 60
Nabholtz, J., Chalabi, N., Radosevic‐Robin, N., Dauplat, M. M., Mouret‐Reynier, M., Praagh, I. V., Servent, V., Jacquin, J. P., Benmammar, K.-E., Kullab, S. A., et al. (2015) · International Journal of Cancer · doi:10.1002/ijc.29952 · Cited by 56
Crozier, J. A., Advani, P. P., LaPlant, B. R., Hobday, T. J., Jaslowski, A. J., Moreno‐Aspitia, A., & Perez, E. A. (2015) · Clinical Breast Cancer · doi:10.1016/j.clbc.2015.08.002 · Cited by 53
Orlando, U. D., Castillo, A. F., Dattilo, M. A., Solano, A. R., Maloberti, P. M., & Podesta, E. J. (2015) · Oncotarget · doi:10.18632/oncotarget.5822 · Cited by 52
Audeh, W. (2014) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s39765 · Cited by 42
Zhang, J., Fan, M., Xie, J., Wang, Z., Wang, B., Zhang, S., Wang, L., Cao, J., Tao, Z., Li, T., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5654 · Cited by 40
Effects of Lovastatin on MDA-MB-231 Breast Cancer Cells: An Antibody Microarray Analysis
Yang, T., Yao, H., He, G., Song, L., Liu, N., Wang, Y., Yang, Y., Keller, E. T., & Deng, X. (2015) · Journal of Cancer · doi:10.7150/jca.13414 · Cited by 35
Self-citationAnticancer properties of Monascus metabolites
Yang, T., Liu, J., Luo, F., Lin, Q., Rosol, T. J., & Deng, X. (2014) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000102 · Cited by 27
Self-citationPivot, X. B., Li, R. K., Thomas, E. S., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2009.07.015 · Cited by 24
Cited by
Pyroptosis: A new frontier in cancer
Fang, Y., Tian, S., Pan, Y., Li, W., Wang, Q., Tang, Y., Yu, T., Wu, X., Shi, Y., Ma, P., et al. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109595 · Cited by 1,049
Association of statin use with clinical outcomes in patients with triple‐negative breast cancer
Nowakowska, M. K., Lei, X., Thompson, M. T., Shaitelman, S. F., Wehner, M. R., Woodward, W. A., Giordano, S. H., & Nead, K. T. (2021) · Cancer · doi:10.1002/cncr.33797 · Cited by 62
Ulug, M. E., Ikram, S., Sayyah, E., & Durdağı, S. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.142602 · Cited by 3
Metadata
- Authors
- Yao, H., He, G., Yan, S., Chen, C., Song, L., Rosol, T. J., & Deng, X.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2016-09-27
- Volume
- 8
- Issue
- 1
- Pages
- 1913-1924
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2523763608
- Cited by
- 394
- References
- 87
- FWCI
- 10.55
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.